Balu Balasubramanian - Pyxis Oncology Interim Officer
| PYXS Stock | USD 2.01 0.18 9.84% |
Insider
Balu Balasubramanian is Interim Officer of Pyxis Oncology
| Address | 321 Harrison Avenue, Boston, MA, United States, 02118 |
| Phone | 617 221 9059 |
| Web | https://www.pyxisoncology.com |
Pyxis Oncology Management Efficiency
The company has return on total asset (ROA) of (0.2106) % which means that it has lost $0.2106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3934) %, meaning that it created substantial loss on money invested by shareholders. Pyxis Oncology's management efficiency ratios could be used to measure how well Pyxis Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to drop to -0.58 in 2024. At this time, Pyxis Oncology's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 16.4 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 111 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| RPh PharmD | Elevation Oncology | 40 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| John Lewicki | Mereo BioPharma Group | 72 | |
| Covadonga Paeda | Altamira Therapeutics | N/A | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| Christine MBA | Hookipa Pharma | 59 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| MS MBA | Inozyme Pharma | 47 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Janetta Trochimiuk | PDS Biotechnology Corp | 61 | |
| Prof MD | Hookipa Pharma | 80 | |
| David Dornan | Elevation Oncology | 46 | |
Management Performance
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.21 |
Pyxis Oncology Leadership Team
Elected by the shareholders, the Pyxis Oncology's board of directors comprises two types of representatives: Pyxis Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pyxis. The board's role is to monitor Pyxis Oncology's management team and ensure that shareholders' interests are well served. Pyxis Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pyxis Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Balu Balasubramanian, Interim Officer | ||
| Jan Pinkas, Chief Officer | ||
| Pamela MBA, Chief Officer | ||
| Charles Gombar, Senior Management | ||
| MBA MBA, CoFounder Chairman | ||
| MD FACP, Chief Officer | ||
| Jitendra Wadhane, Senior Officer | ||
| MBA MD, President CEO | ||
| Martina BS, Interim Officer | ||
| Stephen MBA, Senior Officer |
Pyxis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pyxis Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (3.99) % | ||||
| Current Valuation | (4.75 M) | ||||
| Shares Outstanding | 59.47 M | ||||
| Shares Owned By Insiders | 24.54 % | ||||
| Shares Owned By Institutions | 54.50 % | ||||
| Number Of Shares Shorted | 5.84 M | ||||
| Price To Book | 0.78 X | ||||
| Price To Sales | 7.40 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.